Bristol Myers Squibb has welcomed TGA registration of SOTYKTU (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. …
BMS welcomes TGA registration of its first-in-class TYK2 inhibitor
December 6, 2022 Latest NewsBioPharma
Latest Video
New Stories
-
The 'Week in Review' - 27 January
January 27, 2023 - - Podcast -
Forget about experts and terms of reference until we get a transparent process
January 27, 2023 - - Latest News -
Australia Day recognition for senior officials and pharmacy leaders
January 27, 2023 - - Latest News -
Is this a change of heart from the former health department secretary?
January 27, 2023 - - Latest News -
New chair for Australian genomics industry organisation
January 26, 2023 - - Australian Biotech -
MEDLAB receives Import Certificate from UK Home Office for NanaBis
January 26, 2023 - - Australian Biotech -
Alterity Therapeutics launches ATH434 Phase 2 clinical trial in Italy
January 26, 2023 - - Australian Biotech